Rare Diseases
Page 3 • 12 itemsGain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026
CLINUVEL gets final EMA scientific advice for pivotal Phase III vitiligo study comparing SCENESSE with NB-UVB therapy, set to begin second half 2026.
EU Orphan Drug Designation: Successes & Market Access in Rare Cancers
This article delves into the EU Orphan Drug Designation process, showcasing successes and market access strategies for rare cancer treatments like XYZ.
EU Pharmaceutical Legislation Reform: Impact on Orphan Drugs & Market Exclusivity
This article delves into the EU pharmaceutical legislation reform and its implications for orphan drugs, focusing on market exclusivity and patient access.
Belite Bio Submits New Drug Application for Tinlarebant to Treat Stargardt Disease Following Positive Phase 3 Results
Belite Bio initiates rolling NDA submission for tinlarebant after Phase 3 DRAGON trial showed 35.7% reduction in retinal lesion growth for Stargardt disease patients.
Pembrolizumab Plus Lenvatinib Shows Promise for Rare Clear Cell Gynecological Cancers in Phase 2 Trial
LARA Phase 2 trial published in The Lancet Oncology demonstrates promising clinical activity of pembrolizumab plus lenvatinib for recurrent clear cell cancers.
Polycythemia Vera Market Transformation: 9 Companies Including Protagonist Therapeutics with Rusfertide to Enter by 2036
Nine pharmaceutical companies are advancing polycythemia vera treatments through clinical trials, with Protagonist Therapeutics' rusfertide leading market expansion by 2036.
Ipsen's Ojemda (Tovorafenib) Becomes First Targeted Therapy for Pediatric Brain Tumors in EU
Ipsen's Ojemda receives EU approval as first targeted therapy for pediatric low-grade glioma, addressing critical unmet need in rare brain tumors.
Karyopharm Phase 3 SENTRY Trial Results Selected for ASCO 2026 Late-Breaking Presentation in Myelofibrosis
Karyopharm's Phase 3 SENTRY trial in myelofibrosis earns prestigious late-breaking oral presentation slot at ASCO 2026, signaling potential breakthrough results.
![EMA Conditional Approval 2026: Insights from [Drug Name] Case Study](/uploads/articles/ema-conditional-approval-drugname-market-access-2026.webp)
EMA Conditional Approval 2026: Insights from [Drug Name] Case Study
This article delves into the EMA Conditional Approval 2026, highlighting key insights from the [Drug Name] case study for [indication] and its significance.
Real-World Evidence EU Drug Development: EMA's Hybrid Trial Framework
The EMA's Hybrid Trial Framework revolutionizes drug development by integrating real-world evidence, improving outcomes for patients with chronic conditions.
EU HTA Regulation 2027: What You Need to Know for Market Access & Pricing
The EU HTA Regulation 2027 will reshape market access and pricing strategies for drugs, including XYZ for chronic conditions, requiring industry adaptation.
EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Development & Market Exclusivity
The EU's pharmaceutical legislation reform aims to enhance orphan drug development and market exclusivity, significantly influencing treatments for rare diseases.